Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA.
Am J Gastroenterol. 2011 Nov;106(11):1872-9. doi: 10.1038/ajg.2011.232.
Although iron supplementation is commonly prescribed, the amount of elemental iron needed to achieve clinical efficacy, and the optimal method of supplementation, are under debate. Use of intravenous (IV) iron replacement is increasingly being advocated. We explore the physiology of iron supplementation, review clinical data suggesting that the typical oral dosing of iron may be excessive, and compare IV and oral methods of iron supplementation with a focus on inflammatory bowel disease (IBD). Both IV and oral iron can effectively raise hemoglobin levels in iron-deficiency anemia. There is no evidence that IV iron can raise hemoglobin at a faster pace. Side effects of oral iron are probably related to the relatively high doses of elemental iron that are typically prescribed. Emerging data suggest that low-dose iron has comparable efficacy, with fewer side effects. In IBD, both oral and IV iron are effective, and there is no convincing evidence that oral iron activates or exacerbates clinical symptoms. The use of a low starting dose of oral iron, such as one ferrous sulfate tablet per day, for treatment of iron deficiency is worth considering.
虽然补铁治疗通常被广泛应用,但为了达到临床疗效所需的铁元素剂量,以及最佳的补充方式,仍存在争议。目前越来越提倡使用静脉(IV)补铁。我们探讨了铁补充的生理学机制,回顾了一些临床数据,这些数据表明,典型的口服补铁剂量可能过高,并比较了静脉内和口服补铁方法,重点是炎症性肠病(IBD)。静脉内和口服铁都可以有效地提高缺铁性贫血患者的血红蛋白水平。没有证据表明静脉内铁可以更快地提高血红蛋白水平。口服铁的副作用可能与通常开出的较高剂量的元素铁有关。新出现的数据表明,低剂量铁具有相当的疗效,副作用更少。在 IBD 中,口服和静脉内铁都有效,没有令人信服的证据表明口服铁会激活或加重临床症状。对于缺铁的治疗,值得考虑使用低起始剂量的口服铁,例如每天一片硫酸亚铁。